Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -2.24%67 EPS without NRI is kr0.04 as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 663 Medical Devices & Instruments companies, Medclair AB ranks worse than 150829.41% on this metric.
Medclair AB's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was kr0.04.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.04.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Medclair AB's EPS without NRI or its related term are showing as below:
During the past 11 years, Medclair AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 59.70% per year. The lowest was -7.70% per year. And the median was 12.10% per year.
NGM:MCLR's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Medclair AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was kr0.04.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.04.
Medclair AB's EPS (Basic) for the
three
months ended in Mar. 2026 was kr0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.04.
Medclair AB (NGM:MCLR) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Medclair AB EPS without NRI Related Terms
Medclair AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for Medclair AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Medclair AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Medclair AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a EPS without NRI of kr0.04 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #999999 out of 663 companies in the Medical Devices & Instruments industry.
Is Medclair AB's EPS without NRI too high?
Medclair AB's current EPS without NRI is kr0.04. Based on the distribution chart, Medclair AB ranks #999999 out of 663 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #999999 out of 663 companies for EPS without NRI. This places Medclair AB in the lower half of its industry. The industry median EPS without NRI is 8.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.00, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current EPS without NRI is kr0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current EPS without NRI is kr0.04. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current EPS without NRI is kr0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
EPS without NRI: kr0.04
GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score
Get the complete analysis for NGM:MCLR
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
